Additionally, most HCC cell lines express high EGFR levels and, in these cell lines, the researchers observed a synergistic effect between lenvatinib and the small-molecule EGFR inhibitors (gefitinib or erlotinib). Here, EGFR is linked to hepatocellular carcinoma.